S1038
Clinical – Sarcoma, skin cancer, malignant melanoma
ESTRO 2026
chordoma (n = 93) or chondrosarcoma (n = 24) were included. The median age at diagnosis was 57.4 years (range, 7.50-82.0), and 64.1% were male. The ECOG performance status was 0–1 in 86% of patients.The most common histological subtype was conventional chordoma, accounting for 71.8% (n = 84), followed by conventional chondrosarcoma in 12% (n = 14).The median follow-up was 3.96 years (range, .65, 7.26 years). Eight patients were treated recently and did not complete six months of post-treatment follow-up, and 15 patients were censored from local control analyses due to loss to follow-up.Four patients (3.4%) discontinued PBT prematurely; all discontinuations due to non-proton treatment-related issues, while 113 patients (96.6%) completed the prescribed course. Grade 3 acute toxicity occurred in 18 patients (15.4%), with no grade 4 or 5 toxicities reported.The median PFS and OS were not reached at the time of analysis.The estimated 1, and 5-year OS rates were 100%, and 81.5% (73.2-90.8%), respectively.The corresponding PFS rates at 1, and 5 years were 91.1% (CI 85.7-96.8%), and 60.7% (CI 47.9- 76.8%), respectively. The local control rates were 97% (CI 93.7-100%) at 1 year and 85.3% (CI 74.6-97.7%) at 5 years. Conclusion: Proton beam therapy for non-BoS chordoma and chondrosarcoma at the Christie demonstrates excellent local control and survival outcomes with an acceptable toxicity profile. These results support PBT as an effective and well-tolerated modality for these rare and challenging tumours. References: 1. Stacchiotti S, Sommer J. Chordoma: a tumor between bone and soft tissue. Lancet Oncol. 2015; 16(2):e43-51.2. DeLaney TF et al. Proton and heavy-ion radiotherapy for skull base and spinal chordomas. J Clin Oncol. 2014;32(26):2906-2912.3. Holliday EB et al. Outcomes of patients with chondrosarcoma of the spine treated with proton therapy. Int J Rdiat Oncol Biol Phys. 2021;110(1):221-229. Keywords: Chordoma, chondrosarcoma, Proton beam therapy Digital Poster 2337 The role of Radiotherapy in the multidisciplinary management of radiation-associated angiosarcoma of the breast: A referral center experience. Albina Allajbej 1 , Alicia Mateo Rejas 1 , Anna Cavallo 2 , Chiara Airoldi 3 , Elena Palassini 4 , Massimiliano Gennaro 5 , Paola Collini 6 , Laura Lozza 1 , Umberto Cortinovis 7 , Rosalba Miceli 3 , Alessandro Gronchi 8 , Emanuele Pignoli 2 , Silvia Stacchiotti 4 , Claudia Sangalli 1
multidisciplinary recommendations. For definitive cases, the radiotherapy dose was 75.6 Gy (RBE) in 42 fractions, and for postoperative cases, 70.2 Gy (RBE) in 39 fractions.Acute toxicity was graded using CTCAE v4.0, with grade ≥ 3 events summarised. Overall survival (OS) was calculated from the date of diagnosis until death or last follow-up, and progression-free survival (PFS) from the end of PBT until local or distant recurrence, death, or last follow-up. Kaplan–Meier estimates were used for survival and local control
analyses. Results:
A total of 117 patients with histologically confirmed
Made with FlippingBook - Share PDF online